Segmental allergen challenge

PreclinicalBiologic

UUniversity of Wisconsin, Madison

Segmental allergen challenge is one of 22 biologic programs targeting Allergic Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic DiseaseActive, not recruiting

Allergic DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Allergic Disease

#DrugCompanyPhaseTrials

Taxol

Teva

Approved

—2

Alvesco

AAzurity Pharmaceuticals

Approved

—3

Foradil

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Allegra

Claritin

Benadryl

Taxotere

Pulmicort

Celestone

Sudafed

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune Response1 trial

Airway Immune Response to Allergens (Use Lay Language Here)

Unknown status·JJOSALYN CHO·Phase 1·NCT04619017·12 enrolled

Allergic Disease1 trial

Functional Activity of Airway Eosinophils in Allergic Disease

Completed·UUniversity of Wisconsin, Madison··NCT01026532·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Segmental allergen challenge. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Segmental allergen challenge compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Segmental allergen challenge. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Wisconsin, Madison

Segmental allergen challenge

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune Response1 trial

Allergic Disease1 trial

References

Drug Info

Quick Facts

Related News